A prospective study of heterologous versus homologous prime-boost immunization with ChAdOx1 nCoV-19 AstraZeneca (AZ) and BNT162b2 Pfizer-BioNTech (BNT) in liver transplant recipients
Latest Information Update: 23 Aug 2022
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 23 Aug 2022 New trial record
- 26 Jun 2022 Results presented at The International Liver Congress 2022